01167.HK
Jacobio Pharmaceuticals Group Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 4.60
−0.65%Year over year
Reported trailing growth
- Revenue
- +261.8%
- EBITDA
- +1109.0%
- EBIT
- +809.0%
- EPS
- +1203.6%
- Free cash flow
- +1234.8%
- Operating cash flow
- +1424.3%
Forward estimates
Based on analyst estimates
- Revenue
- -97.2%
- EBITDA
- -95.2%
- EPS
- -98.4%
Three-year CAGR
- Revenue
- -18.3%
- EBITDA
- +19.2%
- EBIT
- +12.0%
- Net income
- +8.7%
- EPS
- +10.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026